BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In trading on Wednesday, shares of BridgeBio Pharma Inc (Symbol: BBIO) crossed below their 200 day moving average of $28.50, changing hands as low as $28.32 per share. BridgeBio Pharma Inc shares ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

NASDAQ:BBIO opened at $34.90 on Friday. The firm has a market cap of $6.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.07. The company’s 50-day moving average is $32.68 and its ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.